Writing in the journal European Urology, a research team led by Hannelore Heemers, Ph.D., of Cleveland Clinic鈥檚 Lerner Research Institute Department of Cancer Biology, and James Mohler, M.D., chair of the Department of Urology at Roswell Park Cancer Institute in Buffalo, has demonstrated that when genomic fingerprinting is performed on only a single tumor sample, a smaller but more aggressive tumor could potentially be missed.
The finding underscores the importance of new evidence that prostate tumors can be genetically different within an individual patient, which carries important implications for patients and oncologists.
For the study, 鈥�Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators,鈥� the team used next-generation sequencing techniques to genotype prostate tumors from four men who underwent radical prostatectomy at Roswell Park. They also examined public data from the Cancer Genome Atlas to confirm their findings.
鈥淲e examined the molecular composition of heterogeneous cancerous tumors in a patient鈥檚 prostate. We found a lot of genetic differences among these tumors, and concluded that information from a single cancer biopsy is not sufficient to guide treatment decisions,鈥� said Dr. Heemers. 鈥淧recise treatment is more complicated and the findings demonstrate a weakness in current genetic fingerprinting in prostate cancer.鈥�
鈥淗igh risk prostate cancers differ genetically among patients, among the different tumors within an individual patient and even within different sections of a single tumor,鈥� said Dr. Mohler. 鈥淐linicians need to be careful about using the information from a gene-based test, because the analysis may not have been performed on the most aggressive portion of a man鈥檚 prostate cancer.鈥�
In 鈥�Disrupting the Status Quo in Prostate Cancer Diagnosis,鈥� an editorial published in the same journal, Alastair David Lamb, MB.ChB., Ph.D., of Cambridge University Hospitals, and co-authors write: 鈥淪everal aspects of this study are impressive. [The authors] addressed an important clinical and molecular question: What effect does tumor heterogeneity have on decision making in prostate cancer, specifically, with respect to molecular taxonomies of the disease?鈥�
The study authors note that the use of genomic analysis to personalize treatment plans is in its infancy and that many more large studies will be required to develop next-generation prognostic tools that can be relied on to guide treatment selection and planning for men with prostate cancer.
RSS